Financials data is unavailable for this security.
View more
Year on year JCR Pharmaceuticals Co Ltd grew revenues 24.83% from 34.34bn to 42.87bn while net income improved 46.01% from 3.77bn to 5.51bn.
| Gross margin | 71.44% |
|---|---|
| Net profit margin | -1.14% |
| Operating margin | 2.11% |
| Return on assets | -0.39% |
|---|---|
| Return on equity | -0.77% |
| Return on investment | -0.57% |
More ▼
Cash flow in JPYView more
In 2024, JCR Pharmaceuticals Co Ltd increased its cash reserves by 41.26%, or 5.48bn. The company earned 9.31bn from its operations for a Cash Flow Margin of 21.72%. In addition the company used 2.69bn on investing activities and also paid 2.03bn in financing cash flows.
| Cash flow per share | 25.00 |
|---|---|
| Price/Cash flow per share | 27.71 |
| Book value per share | 451.84 |
|---|---|
| Tangible book value per share | 425.96 |
More ▼
Balance sheet in JPYView more
| Current ratio | 1.65 |
|---|---|
| Quick ratio | 0.9827 |
| Total debt/total equity | 0.5011 |
|---|---|
| Total debt/total capital | 0.3325 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 45.35%. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 0.76% |
|---|---|
| Div growth rate (5 year) | 21.67% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | 7.93 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -105.43 |
More ▼
